ClinicalTrials.gg
AvailableNCT04959240Updated Sep 25, 2023

Expanded Access to Velmanase Alfa

An expanded access record providing Velmanase Alfa in Alpha-Mannosidosis, sponsored by Chiesi Farmaceutici S.p.A.. Available. Per ClinicalTrials.gov, last updated 2023-09-25.

Sponsored by Chiesi Farmaceutici S.p.A. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. alpha-Mannosidosis · Chiesi Farmaceutici S.p.A..

Other kind
Only one
of the 12
Registered
11th of 12
by date

Among the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., this one is the only one of another kind, and was the 11th registered.

alpha-Mannosidosis

24 studies on the registry are indexed under alpha-Mannosidosis; 6 are open to participants now.

Browse alpha-Mannosidosis studies →

Open to participants now

1 of the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 5 alpha-Mannosidosis studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Individual patient expanded access requests may be considered for patients who have no other treatment options.

Read the detailed description

Expanded access may provide access for treatment prior to approval by the local regulatory agency.

03

Conditions studied

  • Alpha-Mannosidosis

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)

Eligibility criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • Also known as: Lamzede, Lamazym, rhLAMAN, recombinant human alpha-mannosidase

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT04959240
Responsible party
Sponsor
First posted
Jul 13, 2021
Last update
Sep 25, 2023

Study contacts

Expanded Access
Contact
GRD.EAP@chiesi.com
(888) 661-9260
Clinical Trials
Contact
clinicaltrials_info@chiesi.com
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion